Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
File TM, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, Seltzer E, Paukner S, Wicha WW, Talbot GH, Gasink LB. File TM, et al. Clin Infect Dis. 2019 Nov 13;69(11):1856-1867. doi: 10.1093/cid/ciz090. Clin Infect Dis. 2019. PMID: 30722059 Free PMC article. Clinical Trial.
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley I, Thye D. File TM Jr, et al. Clin Infect Dis. 2010 Dec 15;51(12):1395-405. doi: 10.1086/657313. Epub 2010 Nov 10. Clin Infect Dis. 2010. PMID: 21067350 Clinical Trial.
SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
File TM Jr, Rewerska B, Vucinic-Mihailovic V, Gonong JRV, Das AF, Keedy K, Taylor D, Sheets A, Fernandes P, Oldach D, Jamieson BD. File TM Jr, et al. Clin Infect Dis. 2016 Oct 15;63(8):1007-1016. doi: 10.1093/cid/ciw490. Epub 2016 Jul 22. Clin Infect Dis. 2016. PMID: 27448679 Clinical Trial.
Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
File TM, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, Seltzer E, Paukner S, Wicha WW, Talbot GH, Gasink LB. File TM, et al. Clin Infect Dis. 2020 May 23;70(11):2459. doi: 10.1093/cid/ciz710. Clin Infect Dis. 2020. PMID: 31626688 Free PMC article. No abstract available.
Reply to Tang and Lai.
File TM, Gelone SP, Schranz J, Alexander E. File TM, et al. Clin Infect Dis. 2020 Sep 12;71(6):1583. doi: 10.1093/cid/ciz1174. Clin Infect Dis. 2020. PMID: 31822883 No abstract available.
Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
Paukner S, Goldberg L, Alexander E, Das AF, Heinrich S, Patel P, Moran GJ, Sandrock C, File TM Jr, Vidal JE, Waites KB, Gelone SP, Schranz J. Paukner S, et al. Among authors: file tm jr. J Glob Antimicrob Resist. 2022 Jun;29:434-443. doi: 10.1016/j.jgar.2021.10.021. Epub 2021 Nov 14. J Glob Antimicrob Resist. 2022. PMID: 34788694 Free article. Clinical Trial.
271 results